Forskare har upptäckt lovande resultat i användningen av hjärtsviktsmedicinen colforsin daropate för behandling av en dödlig form av äggstockscancer kallad höggradig serös äggstockscancer (HGSOC)14.
Colforsin daropates potential
Colforsin daropate, som ursprungligen utvecklades för att behandla akut hjärtsvikt, har visat sig ha flera fördelar i kampen mot HGSOC:
- Det kan döda äggstockscancerceller och krympa tumörer, särskilt i kombination med standardkemoterapin cisplatin1.
- Medicinen verkar selektivt på cancerceller utan att skada frisk vävnad4.
- Den hämmar ett cancerrelaterat protein kallat MYC, som ofta är överaktivt i HGSOC1.
Forskningsresultat
I laboratorietester och djurmodeller har colforsin daropate visat lovande resultat:
- Det orsakade cellcykelarrest och celldöd i odlade HGSOC-celler och sfäroider (cancercellkluster)5.
- Behandlingen minskade tumörtillväxt och förlängde överlevnaden hos möss med äggstockscancer5.
- Medicinen försvagade adhesionen mellan cancerceller i sfäroider, vilket kan göra dem mer sårbara för behandling4.
Betydelse och framtidsutsikter
HGSOC är den vanligaste och dödligaste subtypen av äggstockscancer, med begränsade behandlingsalternativ och hög återfallsfrekvens2. Colforsin daropates unika verkningsmekanism och lovande resultat gör det till en potentiellt värdefull tillgång i kampen mot denna aggressiva cancerform4.
Även om mer forskning krävs innan kliniska prövningar på människor kan påbörjas, ger dessa tidiga resultat hopp om en ny behandlingsmöjlighet för kvinnor som kämpar mot höggradig serös äggstockscancer14.
Citations:
- https://medicalxpress.com/news/2025-01-heart-failure-drug-effectively-lethal.html
- https://www.mayoclinic.org/medical-professionals/obstetrics-gynecology/news/mayo-clinic-pilot-study-pinpoints-resectable-high-grade-serous-ovarian-cancer/mac-20565624
- https://pubmed.ncbi.nlm.nih.gov/22322322/
- https://thedailyguardian.com/medically-speaking/heart-drug-shows-promise-in-fighting-deadly-ovarian-cancer/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11684408/
- https://www.sciencenewstoday.org/new-drug-colforsin-daropate-shrinks-tumors-and-inhibits-growth-in-high-grade-serous-ovarian-cancer
- https://www.news-medical.net/news/20200326/Experimental-heart-disease-drug-may-treat-chemo-resistant-ovarian-cancer.aspx
- https://pharmac.govt.nz/medicine-funding-and-supply/funding-cancer-medicines
- https://news.ki.se/new-immunotherapy-holds-promise-for-ovarian-cancer
- https://www.mdanderson.org/newsroom/generic-heart-medication-shown-to-prolong-ovarian-cancer-patient.h00-158989812.html
- https://www.ahajournals.org/doi/10.1161/ATVBAHA.124.319863
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11850731/
- https://news.ki.se/chemotherapy-rewires-a-novel-resistance-promoting-signaling-pathway-in-ovarian-cancer
- https://pubmed.ncbi.nlm.nih.gov/39914419/
- https://www.aacr.org/blog/2025/01/10/experts-forecast-cancer-research-and-treatment-advances-in-2025/
- https://www.empr.com/news/january-2025-recap-drug-pipeline-updates/
- https://academic.oup.com/eurheartj/article/45/14/1224/7619348
- https://pubmed.ncbi.nlm.nih.gov/39762846/
- https://www.medicalresearch.nsw.gov.au/reducing-risk-of-cardiovascular-disease-after-cancer-treatment/
- https://medicine.uiowa.edu/obgyn/research/recent-research-publications/march-2025
- https://www.nature.com/articles/s41698-025-00808-w
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4017729/
- https://www.onclive.com/view/dr-moore-on-the-2024-fda-approval-of-mirvetuximab-soravtansine-in-ovarian-cancer
- https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1468196/full
- https://www.cancercenter.com/cancer-types/ovarian-cancer/types
- https://documents.cap.org/protocols/Ovary_FT_Perit_1.5.0.0.REL_CAPCP.pdf
- https://www.icr.ac.uk/about-us/icr-news/detail/the-future-of-ovarian-cancer–innovation–treatment-and-hope
- https://www.cancer.org/research/acs-research-highlights/ovarian-cancer-research-highlights/a-new-gene-is-linked-with-the-deadliest-type-of-ovarian-cancer.html
- https://ascopost.com/video-roundtable/overcoming-platinum-resistance-in-ovarian-cancer/stage-iiic-high-grade-serous-ovarian-cancer-after-progression-on-platinum-based-therapy-and-parp-inhibitor/
- https://www.onclive.com/view/fda-grants-fast-track-status-to-vls-1488-for-platinum-resistant-high-grade-serous-ovarian-cancer
- https://ocrahope.org/news/high-grade-serous-carcinoma/
- https://medicalxpress.com/news/2025-01-heart-failure-drug-effectively-lethal.pdf
- https://www.science.org/doi/10.1126/scisignal.ado8303
- https://www.semanticscholar.org/paper/Repurposing-colforsin-daropate-to-treat-MYC-driven-Knarr-Moon/5aec42a77ef7b196fe0af28e1a2416a6689b53f1
- https://www.researchgate.net/publication/385946829_Repurposing_colforsin_daropate_to_treat_MYC-driven_high-grade_serous_ovarian_carcinomas
- https://academic.oup.com/oncolo/article/28/10/e977/7259791
- https://edu360.igcs.org/AssetListing/In-The-Know-6439/January-2025-23062
- https://news.ki.se/new-study-questions-the-effectiveness-of-drugs-for-ovarian-protection-during-cancer-treatment
- https://www.linkedin.com/posts/ktalluri_repurposing-colforsin-daropate-to-treat-myc-driven-activity-7290761157697544194-oewd
- https://www.researchgate.net/figure/BEVACIZUMAB-IN-OVARIAN-CANCER-Clinical-Trials-Ongoing_tbl2_309959711
- https://knowridge.com/2025/02/heart-disease-drug-could-fight-deadly-ovarian-cancer/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9398205/
- https://www.ajmc.com/view/cardiomyopathy-risk-plummets-when-sacubitril-valsartan-taken-with-chemo
- https://newsroom.uvahealth.com/2023/09/14/chemo-drug-prevents-heart-failure/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3830519/
- https://news.cuanschutz.edu/cancer-center/experimental-medication-may-treat-chemo-resistant-ovarian-cancer
- https://www.targetedonc.com/view/novel-therapies-and-combinations-lead-the-way-in-women-s-cancers-in-2024
- https://pubmed.ncbi.nlm.nih.gov/39799740/
- https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-elahere-platinum-resistant-ovarian-cancer
- https://www.aurorahealthcare.org/services/cancer/ovarian-cancer/types
- https://www.nature.com/articles/s41525-024-00447-3
- https://www.targetedonc.com/view/fda-grants-priority-review-to-avutometinib-defactinib-combo-in-kras-ovarian-cancer
- https://www.obermair.info/latest-news/blog/what-is-the-most-aggressive-type-of-ovarian-cancer/
- https://www.mdanderson.org/publications/conquest/generic-heart-medication-may-improve-outcome.h4236-1589835.html
- https://pubmed.ncbi.nlm.nih.gov/39561220/?fc=20220524054416&ff=20241119192233&v=2.18.0.post9+e462414
